NEW YORK (GenomeWeb News) – Xceleron announced today that it will collaborate with JCL Bioassay in offering drug developers access to their respective technologies for drug screening and development applications.

Xceleron said that the partnership will offer clinical design expertise and appropriate analytical platforms for early clinical investigation. It added that between the firms they have developed more than 100 analytical methods for Phase 0 and Phase 1 investigations.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.